Novartis presents JAK inhibitor INC424 Phase I/II trial results
Novartis has licensed INC424 from Incyte for development and commercialisation outside the US, while the rights for the development and commercialisation of INC424 in the US are retained
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.